What's in EA Pharma Co., Ltd.'s pipeline?

EA Pharma Co., Ltd. has 7 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 4 in Phase 1.

Which companies overlap with EA Pharma Co., Ltd.'s portfolio?

Top competitors by shared drug class: Ironwood Pharmaceuticals, Inc., Md Mehedi Shahriar.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ea-pharma-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

EA Pharma Co., Ltd. — Portfolio Competitive Intelligence Brief

EA Pharma Co., Ltd. pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Carogra	Carotegrast methyl	marketed		Integrin alpha-4/beta-1	Immunology
AJM300	AJM300	phase 3
AJG555	AJG555	phase 3	Guanylate cyclase-C agonist	GC-C (guanylate cyclase-C)	Gastroenterology

Therapeutic area mix

Gastroenterology · 1
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ironwood Pharmaceuticals, Inc. · 1 shared drug class
Md Mehedi Shahriar · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for EA Pharma Co., Ltd.:

Cite this brief

Drug Landscape (2026). EA Pharma Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ea-pharma-co-ltd. Accessed 2026-05-14.